Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

President Donald Trump's executive order mandates drugmakers to lower prices to match those in affluent nations, threatening ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

US President Donald Trump signed an executive order requiring drugmakers to lower prices, aligning with international rates.

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...